ALEC

Alector, Inc.

Healthcare
Biotechnology
$204M market cap

Forecast run · Oct 29, 2026Upside rank 556 of 3,186

Model Signal

ForecastQ Daily Probabilities

43.5%

57.7%

43.8%

Analyst Consensus

Recommendation2.50/5 Buy

Last price$1.83

Price target$2.25

Implied move+23.0%

Analysts14

ForecastQ Portfolios

ALEC is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.